手术切除肺腺癌的多组学蛋白基因组分析
研究对51例已知复发状态的手术切除非小细胞肺癌肿瘤进行RNA测序与液相色谱-质谱蛋白质组学分析,提出将高通量RNA与蛋白测量整合为整合生物标志物的框架,并显示其预测肺腺癌复发风险的潜力;同时刻画mRNA与蛋白测量的关系并发现其具有结局特异性。
要点
- 约半数切除的早期肺癌患者复发并死于该病,辅助化疗仅降低5%至8%的风险。
- mRNA与蛋白数据具有独立的生物学与临床重要性,可构建更强效的表达生物标志物。
- mRNA与蛋白测量的关系在肺腺癌中呈结局特异性,支持整合多组学预测复发。
核心结论
- mRNA与蛋白数据具有独立的生物学和临床重要性,可用于构建更高功效的表达生物标志物。
研究设计与样本
- 对51例已知复发状态的手术切除非小细胞肺癌肿瘤生成RNA测序与液相色谱/液相色谱-质谱蛋白质组学数据。
主要发现
- 提出将高通量RNA与蛋白测量纳入整合生物标志物的原理与框架,并显示其预测一组肺腺癌复发风险的潜力。
- 刻画了肺腺癌中mRNA与蛋白测量的关系,并显示该关系具有结局特异性。
临床怎么用
- 可考虑将RNA与蛋白测量整合用于肺腺癌术后复发风险分层与辅助治疗获益人群识别。
- mRNA与蛋白数据可独立贡献信息,支持构建整合表达生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite apparently complete surgical resection, approximately half of resected early-stage lung cancer patients relapse and die of their disease. Adjuvant chemotherapy reduces this risk by only 5% to 8%. Thus, there is a need for better identifying who benefits from adjuvant therapy, the drivers of relapse, and novel targets in this setting. METHODS: RNA sequencing and liquid chromatography/liquid chromatography-mass spectrometry proteomics data were generated from 51 surgically resected non-small cell lung tumors with known recurrence status. RESULTS: We present a rationale and framework for the incorporation of high-content RNA and protein measurements into integrative biomarkers and show the potential of this approach for predicting risk of recurrence in a group of lung adenocarcinomas. In addition, we characterize the relationship between mRNA and protein measurements in lung adenocarcinoma and show that it is outcome specific. CONCLUSIONS: Our results suggest that mRNA and protein data possess independent biological and clinical importance, which can be leveraged to create higher-powered expression biomarkers.
引用
- Sharpnack MF, Ranbaduge N, Srivastava A, et al. Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. J Thorac Oncol. 2018. PMID: 30017829. doi:10.1016/j.jtho.2018.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。